205 related articles for article (PubMed ID: 38760802)
1. Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men.
Crudele L; De Matteis C; Novielli F; Di Buduo E; Petruzzelli S; De Giorgi A; Antonica G; Berardi E; Moschetta A
Biol Sex Differ; 2024 May; 15(1):43. PubMed ID: 38760802
[TBL] [Abstract][Full Text] [Related]
2. US-FLI score - Is it possible to predict the steatosis grade with an ultrasonographic score?
Xavier SA; Monteiro SO; Arieira CM; Castro FD; Magalhães JT; Leite SM; Marinho CM; Cotter JB
Mol Genet Metab; 2021 Mar; 132(3):204-209. PubMed ID: 33558081
[TBL] [Abstract][Full Text] [Related]
3. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases.
Ballestri S; Nascimbeni F; Baldelli E; Marrazzo A; Romagnoli D; Targher G; Lonardo A
Metabolism; 2017 Jul; 72():57-65. PubMed ID: 28641784
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive assessment of hepatic steatosis by ultrasound-derived fat fraction in individuals at high-risk for metabolic dysfunction-associated steatotic liver disease.
Tavaglione F; Flagiello V; Terracciani F; Gallo P; Capparelli E; Spiezia C; De Vincentis A; Palermo A; Scriccia S; Galati G; Napoli N; Daniels SJ; Blau JE; Carlsson B; Khazrai YM; Incalzi RA; Picardi A; Vespasiani-Gentilucci U
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3787. PubMed ID: 38461408
[TBL] [Abstract][Full Text] [Related]
5. Fatty Liver Index (FLI) Identifies Not Only Individuals with Liver Steatosis but Also at High Cardiometabolic Risk.
Carli F; Sabatini S; Gaggini M; Sironi AM; Bedogni G; Gastaldelli A
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834099
[TBL] [Abstract][Full Text] [Related]
6. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
7. Validation of non-invasive indicators in the screening of metabolic dysfunction-associated fatty liver disease: a cross-sectional study among Uighurs in rural Xinjiang.
Guo Y; Hu Y; Yang J; Ma R; Zhang X; Guo H; Wang X; Li Y; Peng X; Zhang S; He J; Guo S
Eur J Med Res; 2023 Dec; 28(1):555. PubMed ID: 38042816
[TBL] [Abstract][Full Text] [Related]
8. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.
Zelber-Sagi S; Webb M; Assy N; Blendis L; Yeshua H; Leshno M; Ratziu V; Halpern Z; Oren R; Santo E
World J Gastroenterol; 2013 Jan; 19(1):57-64. PubMed ID: 23326163
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies.
van Son KC; Te Nijenhuis-Noort LC; Boone SC; Mook-Kanamori DO; Holleboom AG; Roos PR; Lamb HJ; Alblas G; Coenraad MJ; Rosendaal FR; de Mutsert R; Tushuizen ME
Medicine (Baltimore); 2024 Jan; 103(1):e34934. PubMed ID: 38181294
[TBL] [Abstract][Full Text] [Related]
10. Sex and age differences in the association of fatty liver index-defined non-alcoholic fatty liver disease with cardiometabolic risk factors: a cross-sectional study.
Fresneda S; Abbate M; Busquets-Cortés C; López-González A; Fuster-Parra P; Bennasar-Veny M; Yáñez AM
Biol Sex Differ; 2022 Nov; 13(1):64. PubMed ID: 36333736
[TBL] [Abstract][Full Text] [Related]
11. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
[TBL] [Abstract][Full Text] [Related]
12. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.
Carvalhana S; Leitão J; Alves AC; Bourbon M; Cortez-Pinto H
Liver Int; 2014 Jul; 34(6):e111-7. PubMed ID: 24034415
[TBL] [Abstract][Full Text] [Related]
13. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
[TBL] [Abstract][Full Text] [Related]
15. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.
Barrea L; Muscogiuri G; Modica R; Altieri B; Pugliese G; Minotta R; Faggiano A; Colao A; Savastano S
Front Endocrinol (Lausanne); 2021; 12():649496. PubMed ID: 33815296
[TBL] [Abstract][Full Text] [Related]
16. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD.
Ballestri S; Lonardo A; Romagnoli D; Carulli L; Losi L; Day CP; Loria P
Liver Int; 2012 Sep; 32(8):1242-52. PubMed ID: 22520641
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
Curr Obes Rep; 2024 May; ():. PubMed ID: 38809396
[TBL] [Abstract][Full Text] [Related]
18. Population-specific cut-off points of fatty liver index: a study based on the National Health and Nutrition Examination Survey data.
Wu J; Tian S; Li H; Xu Z; Li S; Chen YL; Liang XY; Xiao J; Song JY; She RL; Ma CY; Feng JH; Li ZX; Jiang ZY; Zhang ZW; Wu KN; Kong LQ
BMC Gastroenterol; 2022 May; 22(1):265. PubMed ID: 35624410
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022).
Kouvari M; Chrysohoou C; Damigou E; Barkas F; Kravvariti E; Liberopoulos E; Tsioufis C; Sfikakis PP; Pitsavos C; Panagiotakos D; Mantzoros CS;
Clin Nutr; 2024 Mar; 43(3):900-908. PubMed ID: 38387279
[TBL] [Abstract][Full Text] [Related]
20. Ultrasound Fatty Liver Indicator: A Simple Tool for Differentiating Steatosis From Nonalcoholic Steatohepatitis: Validity in the Average Obese Population.
Nelson SM; Hoskins JD; Lisanti C; Chaudhuri J
J Ultrasound Med; 2020 Apr; 39(4):749-759. PubMed ID: 31647137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
